Branches of biology

Capricor Announces Joint Publication with the US Army Institute of Surgical Research for Cardiosphere-Derived Exosomes as a Potential Therapeutic for Shock

Retrieved on: 
Wednesday, August 4, 2021
Branches of biology, Medical emergencies, Acute pain, Traumatology, Vesicles, Cells, Extracellular vesicle, Vesicle, Major trauma, Coagulopathy, Injury, Shock

LOS ANGELES, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (“Capricor” or “the Company”) (NASDAQ: CAPR), a biotechnology company focused on developing transformative cell and exosome-based therapeutics for treating and preventing a broad spectrum of diseases, announced today the publication, of a manuscript, which shows that cardiosphere-derived exosomes (CDC-EVs) can attenuate kidney damage and promote new blood vessel formation in a preclinical model of acute trauma, both of which are important factors in post-shock recovery. The publication titled, “Extracellular vesicles derived from cardiosphere-derived cells as a potential antishock therapeutic” was published in the international peer-reviewed journal, The Journal of Trauma and Acute Care Surgery in collaboration with researchers at the United States Army Institute of Surgical Research (USAISR).

Key Points: 
  • The publication titled, Extracellular vesicles derived from cardiosphere-derived cells as a potential antishock therapeutic was published in the international peer-reviewed journal, The Journal of Trauma and Acute Care Surgery in collaboration with researchers at the United States Army Institute of Surgical Research (USAISR).
  • The military continues to look for therapeutics that can be delivered in the field to stabilize wounded warriors.
  • While cell therapy held promise in that arena, a lyophilized product that does not require ultra-cold storage is preferable.
  • The goal of the study was to determine the therapeutic potential of CDC-EVs in a rat model of acute traumatic coagulopathy induced by polytrauma and hemorrhagic shock.

ProMIS Neurosciences Issues Chairman’s Memorandum

Retrieved on: 
Wednesday, August 4, 2021
Branches of biology, Biology, Amyloidosis, Life sciences, Alzheimer's disease, Monoclonal antibodies, Aducanumab, Biogen, Amyloid beta, Amyloid, PROMIS, Neurodegeneration

TORONTO and CAMBRIDGE, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, issued today a Chairmans memorandum, commenting on highlights of the recent 2021 Alzheimers Association International Conference (AAIC) with relevance to ProMIS and summarizing the ProMIS poster/oral presentation contributions to the meeting.

Key Points: 
  • TORONTO and CAMBRIDGE, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, issued today a Chairmans memorandum, commenting on highlights of the recent 2021 Alzheimers Association International Conference (AAIC) with relevance to ProMIS and summarizing the ProMIS poster/oral presentation contributions to the meeting.
  • We are in a new era in the fight against Alzheimers, ALS, and other neurodegenerative diseases, stated Eugene Williams, Executive Chairman of ProMIS Neurosciences.
  • The Chairmans memorandum highlights the recent FDA accelerated approval of Biogens Aduhelm (aducanumab) which now provides a regulatory path to approval in AD, opening the door to development of next generation therapies selectively targeting the pathogenic forms of amyloid-beta.
  • ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.

New poll shows a strong base of Canadians overwhelmingly support controlled legal access to psilocybin-assisted therapy; Canadian Psychedelic Association responds with Memorandum of Regulatory Approval (MORA)

Retrieved on: 
Wednesday, August 4, 2021
Psychoactive drugs, Entheogens, Mycotoxins, Organophosphates, Psilocybin, Psychedelic drug, Branches of biology

With public support at an all-time high, the CPA will now focus on introducing evidence-informed regulations to officials at Health Canada.

Key Points: 
  • With public support at an all-time high, the CPA will now focus on introducing evidence-informed regulations to officials at Health Canada.
  • Dr. Kryskow has witnessed firsthand what legal access to psychedelic medicine can do for Canadians in need of new treatment options.
  • Cory Firth, the Executive Director of the Canadian Psychedelic Association is confident the proposed amendments will continue our collaborative effort with Health Canada.
  • 82% of Canadians polled support or somewhat support approval for allowing the use of psilocybin-assisted therapy.

electroCore Announces Publication in PharmacoEconomics Reiterating Economic Benefits of gammaCore for Cluster Headache Outlined by The National Institute for Health and Care Excellence (NICE) Medical Technologies Guidance

Retrieved on: 
Wednesday, August 4, 2021
Headaches, Symptoms and signs, Branches of biology, Medicine, Trigeminal autonomic cephalgia, Migraine, Cluster headache, Hemicrania continua, Headache, Medication overuse headache, International Classification of Headache Disorders

The paper is part of a series that provides insight into the development of UK National Institute for Health and Care Excellence (NICE) medical technologies guidance for new or innovative medical devices or diagnostics.

Key Points: 
  • The paper is part of a series that provides insight into the development of UK National Institute for Health and Care Excellence (NICE) medical technologies guidance for new or innovative medical devices or diagnostics.
  • The aim of the guidance is to support the adoption of clinically effective and cost-saving technologies in the UK National Health Service.
  • PharmacoEconomics reiterating the evidence supporting gammaCores effectiveness and economic benefit provides further support that gammaCore can play an important role in providing value-based therapy commented Iain Strickland, VP Global Sales and Strategy of electroCore.
  • gammaCore is CE-marked in the European Union for the acute and/or prophylactic treatment of primary headache (Migraine, Cluster Headache, Trigeminal Autonomic Cephalalgias and Hemicrania Continua) and Medication Overuse Headache in adults.

AC Immune Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, August 4, 2021
Medical specialties, Branches of biology, Clinical medicine, Vaccination, Alpha-synuclein, Lewy body dementia, Vaccine, Parkinson's disease

LAUSANNE, Switzerland, Aug. 04, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today reported its financial results for the quarter ended June 30, 2021, and provided a corporate update.

Key Points: 
  • Announced an all-stock acquisition of Affiris portfolio of therapeutics targeting alpha-synuclein notably PD01, a clinically validated active vaccine candidate that places AC Immune at the forefront of Parkinsons disease drug development.
  • The study is currently under analysis and AC Immune plans to present the results at an international Alzheimer conference.
  • SupraAntigen is a registered trademark of AC Immune SA in the following territories: AU, EU, CH, GB, JP and RU.
  • Morphomer is a registered trademark of AC Immune SA in CN, CH, GB, JP, and NO.

Six Outstanding Mental Health Researchers Honored by the Brain & Behavior Research Foundation

Retrieved on: 
Wednesday, August 4, 2021
Brain & Behavior Research Foundation, Branches of biology, Neuropsychology, Psychiatry, Articles, Biology

New York, Aug. 04, 2021 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) has announced the winners of its 2021 Klerman and Freedman Prizes, which recognize exceptional clinical and basic research in mental illness.

Key Points: 
  • New York, Aug. 04, 2021 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) has announced the winners of its 2021 Klerman and Freedman Prizes, which recognize exceptional clinical and basic research in mental illness.
  • The Klerman and Freedman prizes recognize innovative thinking and outstanding talent across the field of neuropsychiatry, said Dr. Jeffrey Borenstein, President and CEO of the Brain & Behavior Research Foundation.
  • We applaud these researchers for their groundbreaking work, and we thank our generous donors for supporting scientists in brain and behavior research who are working to produce better treatments, cures, and methods of prevention for mental illness.
  • The prizewinners are selected by the BBRF Scientific Council comprised of 180 pre-eminent mental health researchers.

Creo successfully completes commercial fermentation run

Retrieved on: 
Wednesday, August 4, 2021
Branches of biology, Academic disciplines, Articles, Roy Lipski, Entheogens, Euphoriants, Metabolism, Cannabinoid, Cannabis, PTC Creo, Creo, Fermentation

San Diego, CA August 4, 2021 Creo , an ingredient technology company with a proprietary platform for producing natural cannabinoids without the cannabis plant, announced today the successful completion of its first commercial fermentation run at 28,000 L scale with performance that exceeded the Companys expectations.

Key Points: 
  • San Diego, CA August 4, 2021 Creo , an ingredient technology company with a proprietary platform for producing natural cannabinoids without the cannabis plant, announced today the successful completion of its first commercial fermentation run at 28,000 L scale with performance that exceeded the Companys expectations.
  • The commercial fermentation produced CBGA which is being processed into finished CBGA and CBG for client sampling and sales.
  • Were pleased with the performance of this commercial fermentation run at 28,000 L, which follows our successful demonstration campaign in January said Creos CEO, Roy Lipski.
  • Creo is an ingredients technology company that produces high quality cannabinoids using the natural process of fermentation.

BioNTech Completes Acquisition of Kite’s Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, Maryland

Retrieved on: 
Wednesday, August 4, 2021
Life sciences, Health sciences, Branches of biology, Biotechnology, BioNTech, Drug discovery, Medicinal chemistry, Therapy, Cell therapy

The acquisition strengthens BioNTechs cell therapy pipeline by accelerating the individualized solid tumor Neoantigen TCR cell therapy research and development program.

Key Points: 
  • The acquisition strengthens BioNTechs cell therapy pipeline by accelerating the individualized solid tumor Neoantigen TCR cell therapy research and development program.
  • It also expands the Companys cell therapy capabilities and manufacturing footprint in North America, building on its acquisition of Neon Therapeutics in 2020 .
  • All Kite employees at the Gaithersburg facility were offered employment with BioNTech prior to closing.
  • As the cell therapy leader, Kite has more approved CAR T indications to help more patients than any other company.

Hybrid/Virtual/Decentralized Clinical Trials Market Outlook Report 2021: Hybrid Trial Use and Experience, Provider Selection, Provider Perceptions, Future Predictions, Study Data - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 4, 2021
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Nervous system, Branches of biology, Symptoms and signs, Acute pain, Nociception, Pain, Suffering

The industry had no choice but to adapt to maintain any sort of momentum on clinical development activities.

Key Points: 
  • The industry had no choice but to adapt to maintain any sort of momentum on clinical development activities.
  • The publisher surveyed 109 respondents at sponsors and CROs regarding their experiences with hybrid trials and providers of these services.
  • Though not all reported a smooth, pain-free experience, nearly two-thirds of respondents came away with a positive overall impression of hybrid trials.
  • 83% of respondents expect that the hybrid trial model will be used more frequently than the traditional trial model three years from now.

Asia-Pacific Cell Therapy Market Analysis Report 2021-2028 by Use-type (Clinical-use, Research-use), & Therapy Type (Autologous, Allogeneic) - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 4, 2021
Health, Biotechnology, Life sciences, Health sciences, Branches of biology, Stem cells, Biotechnology, Drug discovery, Medicinal chemistry, Therapy, Cell therapy, SWOT analysis

The "Asia Pacific Cell Therapy Market Size, Share & Trends Analysis Report by Use-type (Clinical-use, Research-use), by Therapy Type (Autologous, Allogeneic) and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Asia Pacific Cell Therapy Market Size, Share & Trends Analysis Report by Use-type (Clinical-use, Research-use), by Therapy Type (Autologous, Allogeneic) and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.
  • The Asia Pacific cell therapy market size is expected to reach USD 2.9 billion by 2028.
  • The market is expected to expand at a CAGR of 14.9% from 2021 to 2028.
  • Chapter 3 Cell Therapy Market Variables, Trends, and Scope
    3.4 Penetration and Growth Prospect Mapping for Therapy Type, 2020
    3.5.1 SWOT Analysis; By factor (Political & Legal, Economic and Technological)
    Chapter 4 Cell Therapy Market: COVID-19 Impact analysis